NCT04866017 2024-10-31
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
BeiGene
Swiss Cancer Institute
Pfizer
University of Ulm
Sun Yat-sen University
Concordia Laboratories Inc.
Centre Francois Baclesse
Intergroupe Francophone de Cancerologie Thoracique
QLT Inc.
QLT Inc.
Cell Genesys
Cell Genesys
Pharmexa A/S